Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction: A Modifiable Therapeutic Target?
- PMID: 35680208
- DOI: 10.1016/j.jcmg.2022.04.008
Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction: A Modifiable Therapeutic Target?
Keywords: cardiac magnetic resonance (CMR); heart failure with preserved ejection fraction (HFpEF); microvascular disease; myocardial fibrosis; pathophysiology; prognosis.
Conflict of interest statement
Funding Support and Author Disclosures Prof Berry is supported by a British Heart Foundation Centre of Research Excellence award (RE/18/6134217). The University of Glasgow, which employs Prof Berry, holds research and consultancy agreements with Abbot Vascular, AstraZeneca, Coroventis, GlaxoSmithKline, HeartFlow, Menarini, Neovasc, Novartis, Siemens Healthcare, and Valo Health. Mr Sykes has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Prevalence and Prognostic Significance of Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.JACC Cardiovasc Imaging. 2022 Jun;15(6):1001-1011. doi: 10.1016/j.jcmg.2021.11.022. Epub 2022 Jan 12. JACC Cardiovasc Imaging. 2022. PMID: 35033490
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical